BioCryst to Report Second Quarter 2025 Financial Results on August 4
BioCryst Pharmaceuticals (Nasdaq: BCRX) has scheduled its second quarter 2025 financial results announcement for Monday, August 4, 2025. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the financial results and provide a corporate update.
Investors can access the live call by dialing 1-844-481-2942 (domestic) or 1-412-317-1866 (international). A live webcast and replay will be available in the investors section at www.biocryst.com.
BioCryst Pharmaceuticals (Nasdaq: BCRX) ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per luned矛 4 agosto 2025. La societ脿 terr脿 una conference call e una webcast alle 8:30 a.m. ET per discutere i risultati finanziari e fornire un aggiornamento aziendale.
Gli investitori potranno partecipare alla chiamata in diretta chiamando il numero 1-844-481-2942 (nazionale) o 1-412-317-1866 (internazionale). Una webcast in diretta e la registrazione saranno disponibili nella sezione investitori su www.biocryst.com.
BioCryst Pharmaceuticals (Nasdaq: BCRX) ha programado el anuncio de resultados financieros del segundo trimestre de 2025 para el lunes 4 de agosto de 2025. La compa帽铆a realizar谩 una llamada conferencia y una transmisi贸n en vivo a las 8:30 a.m. ET para discutir los resultados financieros y ofrecer una actualizaci贸n corporativa.
Los inversionistas pueden acceder a la llamada en vivo marcando al 1-844-481-2942 (nacional) o al 1-412-317-1866 (internacional). La transmisi贸n en vivo y la repetici贸n estar谩n disponibles en la secci贸n de inversionistas en www.biocryst.com.
BioCryst Pharmaceuticals (雮橃姢雼�: BCRX)電� 2025雲� 2攵勱赴 鞛 鞁れ爜 氚滍憸毳� 2025雲� 8鞗� 4鞚� 鞗旍殧鞚�搿� 鞓堨爼頄堨姷雼堧嫟. 須岇偓電� 鞓れ爠 8:30 ET鞐� 旎嵓霟办姢 旖滉臣 鞗轨簮鞀ろ姼毳� 歆勴枆頃橃棳 鞛 鞁れ爜瓿� 須岇偓 鞐呺嵃鞚错姼毳� 瓿奠湢頃� 鞓堨爼鞛呺媹雼�.
韴瀽鞛愲摛鞚� 甑偞 鞝勴檾氩堩樃 1-844-481-2942 霕愲姅 甑牅 鞝勴檾氩堩樃 1-412-317-1866搿� 霛检澊敫� 旖滌棎 彀胳棳頃� 靾� 鞛堨姷雼堧嫟. 霛检澊敫� 鞗轨簮鞀ろ姼鞕� 鞛癌靻§潃 韴瀽鞛� 靹轨厴鞚� www.biocryst.com鞐愳劀 鞝滉车霅╇媹雼�.
BioCryst Pharmaceuticals (Nasdaq : BCRX) a programm茅 l'annonce de ses r茅sultats financiers du deuxi猫me trimestre 2025 pour le lundi 4 ao没t 2025. La soci茅t茅 organisera une conf茅rence t茅l茅phonique et une webdiffusion 脿 8h30 ET pour discuter des r茅sultats financiers et fournir une mise 脿 jour d'entreprise.
Les investisseurs peuvent acc茅der 脿 l'appel en direct en composant le 1-844-481-2942 (national) ou le 1-412-317-1866 (international). Une webdiffusion en direct et un replay seront disponibles dans la section investisseurs sur www.biocryst.com.
BioCryst Pharmaceuticals (Nasdaq: BCRX) hat die Bekanntgabe der Finanzergebnisse f眉r das zweite Quartal 2025 f眉r Montag, den 4. August 2025 angesetzt. Das Unternehmen wird um 8:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die Finanzergebnisse zu besprechen und ein Unternehmensupdate zu geben.
Investoren k枚nnen den Live-Anruf unter der Nummer 1-844-481-2942 (national) oder 1-412-317-1866 (international) verfolgen. Ein Live-Webcast und eine Aufzeichnung sind im Investor-Bereich auf www.biocryst.com 惫别谤蹿眉驳产补谤.
- None.
- None.
RESEARCH TRIANGLE PARK, N.C., July 21, 2025 (GLOBE NEWSWIRE) -- (狈补蝉诲补辩:听BCRX) today announced that the company will report its second quarter 2025 financial results on Monday, August 4, 2025.
BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at .
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO庐 (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit or follow us on .
BCRXW
Contact:
John Bluth
+1 919 859 7910
FAQ
When will BioCryst (BCRX) report Q2 2025 earnings?
How can I access BioCryst's Q2 2025 earnings call?
Where can I find the replay of BioCryst's Q2 2025 earnings webcast?
What time is BioCryst's Q2 2025 earnings call?
